Konakion (Phytomenadione)

Konakion (phytomenadione) acts as a vitamin K replacement to support the coagulation cascade.

• Vitamin K deficiency: restores normal clotting factor activity in patients with deficient levels.
• Hemorrhagic disease of the newborn: provides prophylaxis to newborns at risk of bleeding.
• Anticoagulant therapy reversal: rapidly reverses the effects of warfarin or other vitamin K antagonists.

• Phytomenadione serves as a cofactor for the γ‑carboxylation of glutamate residues on clotting factors II, VII, IX and X in the liver. This post‑translational modification enables calcium binding, essential for assembling the prothrombinase complex and generating thrombin, thereby restoring normal hemostasis.

Adverse reactions to Konakion are generally infrequent but may occur following parenteral or oral administration.

Common Side Effects

• Injection site pain: mild discomfort at the site of intramuscular or intravenous administration.
• Nausea: transient feeling of queasiness after oral dosing.
• Headache: mild headache reported in some patients.
• Fever: low‑grade temperature elevation occasionally observed.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Hemolysis: rare destruction of red blood cells leading to anemia.
• Hypercoagulability: uncommon excessive clot formation, especially in patients with underlying thrombophilia.

When using Konakion, clinicians should observe several safety considerations to minimize risk.

• Assess vitamin K status: evaluate baseline coagulation parameters before administration.
• Monitor anticoagulated patients: check INR or PT values after reversal therapy.
• Use caution in newborns: ensure appropriate dosing and observe for signs of bleeding.
• Avoid in patients with known hypersensitivity: discontinue if allergic reaction occurs.
• Pregnancy and lactation: use only if benefit outweighs potential risk, as data are limited.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Konakion may interact with other medicines that affect coagulation or vitamin K metabolism.

Major Interactions (Avoid)

• Warfarin: concurrent use can blunt anticoagulant effect, requiring dose adjustment.
• Broad‑spectrum antibiotics (e.g., cephalosporins): may reduce gut flora‑derived vitamin K, altering response.
• High‑dose vitamin K supplements: can diminish the intended reversal effect.

Moderate Interactions (Monitor Closely)

• Heparin: combined effect on clotting may increase bleeding risk.
• Oral contraceptives: potential alteration of coagulation balance.
• Lipid‑lowering agents (e.g., statins): may affect vitamin K‑dependent pathways.